Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer.

Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):939-45.

2.

Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.

Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA.

J Natl Cancer Inst. 2009 Oct 21;101(20):1406-11. doi: 10.1093/jnci/djp306. Epub 2009 Sep 9.

3.

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial.

Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, Zenilman JM, De Marzo AM, Platz EA.

Int J Cancer. 2009 May 1;124(9):2082-7. doi: 10.1002/ijc.24144.

4.

Fatty acids and risk of prostate cancer in a nested case-control study in male smokers.

Männistö S, Pietinen P, Virtanen MJ, Salminen I, Albanes D, Giovannucci E, Virtamo J.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1422-8.

5.

Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer.

Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2160-6.

6.

Sexual factors and the risk of prostate cancer.

Rosenblatt KA, Wicklund KG, Stanford JL.

Am J Epidemiol. 2001 Jun 15;153(12):1152-8.

7.

Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study.

Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, Jacobson LP, De Marzo AM, Willett WC, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1573-80.

8.

Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention.

Seña AC, Miller WC, Hobbs MM, Schwebke JR, Leone PA, Swygard H, Atashili J, Cohen MS.

Clin Infect Dis. 2007 Jan 1;44(1):13-22. Epub 2006 Nov 27.

9.

Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study.

Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S, Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, Hakama M.

Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2952-5.

10.

Vasectomy and prostate cancer: a case-control study in a health maintenance organization.

Zhu K, Stanford JL, Daling JR, McKnight B, Stergachis A, Brawer MK, Weiss NS.

Am J Epidemiol. 1996 Oct 15;144(8):717-22.

11.

Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer.

Chen YC, Huang YL, Platz EA, Alderete JF, Zheng L, Rider JR, Kraft P, Giovannucci E, Sutcliffe S.

Cancer Causes Control. 2013 Jan;24(1):175-80. doi: 10.1007/s10552-012-0103-y. Epub 2012 Nov 21.

12.

Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study.

Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, Willett WC, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):260-9.

13.
14.

Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan.

Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK.

Cancer Causes Control. 2005 Apr;16(3):263-73.

PMID:
15947878
15.

Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms.

Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA.

Am J Epidemiol. 2005 Nov 1;162(9):898-906. Epub 2005 Sep 21.

16.

Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center.

Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S.

J Clin Oncol. 2008 Dec 20;26(36):5923-9. doi: 10.1200/JCO.2008.16.8807. Epub 2008 Nov 17.

17.
18.

An iatrogenic confounding variable.

Albertsen PC.

J Natl Cancer Inst. 2009 Oct 21;101(20):1368-9. doi: 10.1093/jnci/djp311. Epub 2009 Sep 9. No abstract available.

19.

Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.

Severi G, Hayes VM, Neufing P, Padilla EJ, Tilley WD, Eggleton SA, Morris HA, English DR, Southey MC, Hopper JL, Sutherland RL, Boyle P, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1142-7.

20.

Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.

Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):962-8.

Items per page

Supplemental Content

Write to the Help Desk